Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

260
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
260
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

796
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

204
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
204
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

163
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
163
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

273
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
273

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Sex Differences in Clinical Outcomes and Loss of Life Expectancy After Aortic Valve Surgery for Infective Endocarditis: A SWEDEHEART Study.

Journal of the American Heart Association·2026
Same author

Oxylipin-mediated metabolic signatures of symbiosis homeostasis and thermal stress in a model sea anemone.

The ISME journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

LIPID MAPS: Powering discovery in lipidomics.

Science signaling·2026

関連する実験動画

Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K

オメガ3多不飽和脂肪酸は,レゾルビンE1とChemR23軸を通して大動脈弁疾患を減少させる

Gonzalo Artiach1, Miguel Carracedo1, Oscar Plunde1

  • 1Department of Medicine (G.A., M.C., O.P., S.T., A.L.-F., H.A., M.B.), Karolinska Institutet, Stockholm, Sweden.

Circulation
|June 9, 2020
PubMed
まとめ
この要約は機械生成です。

オメガ3脂肪酸 (n-3PUFA) とその媒介体であるレゾルビンE1は,大動脈弁の狭窄症 (AVS) の進行を阻害する. この経路をターゲットにすると AVSの新たな治療法が生まれます

キーワード:
カルシフィケーション,生理学的オメガ3脂肪酸心臓弁の病気炎症脂質

さらに関連する動画

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

関連する実験動画

Last Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

科学分野:

  • 心血管生物学
  • リピドミクス
  • 炎症に関する研究

背景:

  • 大動脈弁の狭窄症 (AVS) は,大動脈弁の厚みと化によって特徴づけられる最も一般的な弁性心疾患です.
  • オメガ3 ポリ不飽和脂肪酸 (n-3 PUFA) は心臓血管に有益であり,抗炎症性を持つ特殊な前溶解媒体の前駆体である.
  • AVSの病原性におけるn-3PUFAおよびその派生媒体の役割は,大部分未定のままである.

研究 の 目的:

  • AVS の発現における n-3 PUFA 派生特化プロレゾルビングメディエーターの役割を調査する.
  • レスルヴィンE1が大動脈弁の結石化に影響するかどうかを判断する.

主な方法:

  • 人間の大動脈弁のリピドミクとトランスクリプトミク分析
  • 機械学的研究のためにアポエ/-マウスとワイヤの損傷モデルを使用した.
  • 固有のn-3PUFA合成とレゾルビンE1受容体 (ChemR23) の作用を研究した.

主要な成果:

  • n - 3 PUFAの組み込みは,ヒトの静脈弁のカルシ化された領域よりも非カルシ化された領域で高かった.
  • リゾルビンE1は,カルシフィケーションの領域で調節されず,カルシフィケーションを阻害しました.
  • 内生性n-3PUFAの合成が強化されたマウスは,弁のカルシフィケーションが減少し,心臓の機能が改善された.
  • レスルビンE1受容体を阻害することで,これらの有益な効果は廃止された.

結論:

  • n-3PUFA由来のレゾルビンE1とその受容体ChemR23軸は,AVSの進行を抑制するために不可欠です.
  • この経路はAVS患者にとって新たな治療目標となる可能性があります.